Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)

Clinical Epigenetics

Table 3 Other potential non-approved HDACis for PTCL

Agent	Last update year	Target	Main diseases under research	Highest phase	Clinical trial registration number (e.g.)
Nanatinostat (VRx-3996) [52]	2021	Class I HDACs	EBV⁺ lymphoma	II	NCT03397706, NCT05011058
Ricolinostat (ACY-1215) [100]	2021	HDAC6	R/R lymphoma, MM, and breast cancer	Ib/II	NCT02091063
Citarinostat (ACY-241) [102]	2023	HDAC1, 2, 6	Lymphoma, MM, pancreatic cancer, and NSCLC	I	NCT02400242, NCT02635061
PCI-34051 [103,104,105]	2021	HDAC8	TCL, CC, HCC, and neuroblastoma	NA	NA
Baicalein [38]	2019	HDAC1, 8	TCL, NSCLC, CC, renal interstitial fibrosis, and influenza	II	NCT03830684, CTR20182427
AR-42 [107]	2018	Pan-HDACs	MM, TCL, BCL, and AML	I	NCT01129193

NA Not acquired, MM Multiple myeloma, HL Hodgkin lymphoma, TCL T-cell lymphoma, BCL B-cell lymphoma, FL Follicular lymphoma, MSS CRC microsatellite-stable colorectal cancer, NHL Non-Hodgkin lymphoma, BCP-ALL B-cell precursor acute lymphoblastic leukemia, PV Polycytemia vera, CMN Chronic myeloproliferative neoplasms, DMD Duchenne muscular dystrophy, EBV+ Epstein-Barr virus-positive, R/R relapsed and refractory, NSCLC Non-small cell lung cancer, CC Colon cancer, HCC Hepatocellular carcinoma, AML Acute myeloid leukemia.

ISSN: 1868-7083